Back to Journals » Open Access Journal of Clinical Trials » Volume 1 » Default

Neuroprotective compounds and innovative therapeutic strategies for Parkinson’s disease: experimental and clinical studies

Authors Fabio Blandini

Published 30 September 2009 Volume 2009:1(Default) Pages 1—15

DOI https://doi.org/10.2147/OAJCT.S4660

Review by Single-blind

Peer reviewer comments 2

Fabio Blandini

Interdepartmental Research Center for Parkinson’s Disease (CRIMP), IRCCS Neurological Institute “C. Mondino Foundation”, Pavia, Italy

Abstract: Identifying new therapeutic strategies capable of modifying the course of Parkinson’s disease (PD) is currently one of the major goals for the researchers of this field. Various mechanistic definitions have been proposed to describe the hypothetical ability of a therapeutic intervention to prevent, block or reverse the neurodegenerative process underlying PD. The general term “neuroprotection” has been related to the capacity of interfering with the ongoing process of neuronal cell death, in order to slow or halt disease progression, while a term such as “neurorestoration” would apply to any intervention capable of increasing the number of surviving dopaminergic neurons. Although none of the therapeutic approaches tested in PD patients has so far shown the ability to stop or reverse disease progression, a certain degree of neuroprotection can be achieved with compounds that are already available in the pharmacological armamentarium of the neurologist. Treatment with dopamine agonists or MAO-B inhibitors, particularly when started in the very early phases of the disease, may play disease-modifying effects and even L-DOPA, at low doses, may be slightly neuroprotective. For a true neurorestorative intervention, promising perspectives are being provided by neurotrophic factors and stem cells, which, however, still need to unveil their full potential.

Keywords: L-DOPA, dopamine agonists, MAO-B inhibitors, trophic factors, stem cells

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Current perspectives in stem cell research for knee cartilage repair

Orth P, Rey-Rico A, Venkatesan JK, Madry H, Cucchiarini M

Stem Cells and Cloning: Advances and Applications 2014, 7:1-17

Published Date: 16 January 2014

Biomarkers for osteoarthritis: investigation, identification, and prognosis

Zhai G, Aref Eshghi E

Current Biomarker Findings 2012, 2:19-28

Published Date: 29 June 2012

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011